KEYMAKER-U01 サブスタディ 01J:クリステン・ラット肉腫ウイルス癌遺伝子相同体(KRAS)G12C変異を有する非小細胞肺癌(NSCLC)患者におけるペンブロリズマブとMK-1084の併用に関する研究(MK-3475-01J/KEYMAKER-U01J)
KEYMAKER-U01 サブスタディ 01J:進行または転移性非扁平上皮非小細胞肺癌(NSCLC)のKRAS G12C変異を有する患者の一次治療を目的とした、研究薬のロールアーム方式による無作為化第2相アンブレラ試験
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Toll Free Number
- 電話番号:1-888-577-8839
- メール:Trialsites@msd.com
研究場所
-
-
Florida
-
Clermont、Florida、アメリカ、34711
- 募集
- Clermont Oncology Center ( Site 0041)
-
コンタクト:
- Study Coordinator
- 電話番号:386-538-3169
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58102
- 募集
- Sanford Health Roger Maris Cancer Center ( Site 0039)
-
コンタクト:
- Study Coordinator
- 電話番号:701-234-2000
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57104
- 募集
- Sanford Cancer Center Oncology Clinic ( Site 0038)
-
コンタクト:
- Study Coordinator
- 電話番号:605-328-8000
-
-
-
-
Lombardy
-
Milan、Lombardy、イタリア、20133
- 募集
- Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 0175)
-
コンタクト:
- Study Coordinator
- 電話番号:00390223903829
-
-
-
-
-
Kyiv、ウクライナ、03022
- 積極的、募集していない
- VISION PARTNER Medical Centre ( Site 0135)
-
Kyiv、ウクライナ、03151
- 募集
- LLC "MEDICAL CENTER DOBROBUT-CLINIC" ( Site 0138)
-
コンタクト:
- Study Coordinator
- 電話番号:+380671502987
-
-
Cherkasy Oblast
-
Cherkasy、Cherkasy Oblast、ウクライナ、18009
- 募集
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139)
-
コンタクト:
- Study Coordinator
- 電話番号:+380472370123
-
-
Dnipropetrovsk Oblast
-
Kryvyi Rih、Dnipropetrovsk Oblast、ウクライナ、50000
- 募集
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465)
-
コンタクト:
- Study Coordinator
- 電話番号:+380677490687
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk、Ivano-Frankivsk Oblast、ウクライナ、76018
- 募集
- Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132)
-
コンタクト:
- Study Coordinator
- 電話番号:380978411455
-
-
Kirovohrad Oblast
-
Kropyvnytskyi、Kirovohrad Oblast、ウクライナ、25011
- 募集
- Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467)
-
コンタクト:
- Study Coordinator
- 電話番号:+380958718674
-
-
Lviv Oblast
-
Lviv、Lviv Oblast、ウクライナ、79059
- 募集
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133)
-
コンタクト:
- Study Coordinator
- 電話番号:+380677724757
-
-
Vinnytsia Oblast
-
Vinnitsya、Vinnytsia Oblast、ウクライナ、21029
- 募集
- Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 0131)
-
コンタクト:
- Study Coordinator
- 電話番号:380953105783
-
-
Zakarpattia Oblast
-
Uzhhorod、Zakarpattia Oblast、ウクライナ、88000
- 募集
- Uzhhorod Municipal Multidisciplinary Clinical Hospital of Uzhhorod City Council ( Site 0137)
-
コンタクト:
- Study Coordinator
- 電話番号:+380506847086
-
-
-
-
Overijssel
-
Deventer、Overijssel、オランダ、7416 SE
- 募集
- Deventer Ziekenhuis ( Site 0272)
-
コンタクト:
- Study Coordinator
- 電話番号:+31570536437
-
-
South Holland
-
Leiden、South Holland、オランダ、2333 ZA
- 募集
- Leids Universitair Medisch Centrum ( Site 0273)
-
コンタクト:
- Study Coordinator
- 電話番号:+31715566376
-
-
-
-
Attica
-
Athens、Attica、ギリシャ、106 76
- 募集
- Evangelismos General Hospital of Athens ( Site 0200)
-
コンタクト:
- Study Coordinator
- 電話番号:+302132041631
-
-
-
-
-
Seville、スペイン、41009
- 募集
- Hospital Universitario Virgen de la Macarena ( Site 0093)
-
コンタクト:
- Study Coordinator
- 電話番号:+34 671560092
-
-
-
-
Bangkok
-
Bangkok、Bangkok、タイ、10300
- 募集
- Bangkok Metropolitan Administration Medical College and Vajira Hospital ( Site 0351)
-
コンタクト:
- Study Coordinator
- 電話番号:+6622443461
-
Bangkok、Bangkok、タイ、10700
- 募集
- Faculty of Medicine Siriraj Hospital ( Site 0350)
-
コンタクト:
- Study Coordinator
- 電話番号:+6624194488-9
-
-
-
-
Region M. de Santiago
-
Santiago、Region M. de Santiago、チリ、7560908
- 募集
- Centro de Oncología de Precisión ( Site 0160)
-
コンタクト:
- Study Coordinator
- 電話番号:+56991612199
-
Santiago、Region M. de Santiago、チリ、7500921
- 募集
- Fundacion Arturo Lopez Perez ( Site 0167)
-
コンタクト:
- Study Coordinator
- 電話番号:56224205098
-
Santiago、Region M. de Santiago、チリ、8420383
- 募集
- Bradfordhill ( Site 0168)
-
コンタクト:
- Study Coordinator
- 電話番号:+56998744662
-
-
-
-
-
Adana、トルコ(Türkiye)、34010
- 募集
- Koç Üniversitesi Hastanesi ( Site 0142)
-
コンタクト:
- Study Coordinator
- 電話番号:08502508250-21251
-
Adana、トルコ(Türkiye)、1250
- 募集
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
-
コンタクト:
- Study Coordinator
- 電話番号:+905537766235
-
Ankara、トルコ(Türkiye)、6230
- 募集
- Hacettepe Universite Hastaneleri ( Site 0140)
-
コンタクト:
- Study Coordinator
- 電話番号:+90 312 305 50 00
-
Ankara、トルコ(Türkiye)、06680
- 募集
- Liv Hospital Ankara ( Site 0146)
-
コンタクト:
- Study Coordinator
- 電話番号:905469299990
-
-
Kayseri
-
Talas、Kayseri、トルコ(Türkiye)、38039
- 募集
- Erciyes University ( Site 0145)
-
コンタクト:
- Study Coordinator
- 電話番号:905366550924
-
-
-
-
Northern Savonia
-
Kuopio、Northern Savonia、フィンランド、70200
- 募集
- Kuopion Yliopistollinen Sairaala ( Site 0261)
-
コンタクト:
- Study Coordinator
- 電話番号:+35817173311
-
-
Pohjanmaa
-
Vaasa、Pohjanmaa、フィンランド、65130
- 募集
- Vaasan Keskussairaala ( Site 0263)
-
コンタクト:
- Study Coordinator
- 電話番号:+358405533545
-
-
Southwest Finland
-
Turku、Southwest Finland、フィンランド、20520
- 募集
- Turku University Hospital ( Site 0262)
-
コンタクト:
- Study Coordinator
- 電話番号:+35823138709
-
-
Uusimaa
-
Helsinki、Uusimaa、フィンランド、00290
- 募集
- HYKS Syöpätautien klinikka ( Site 0260)
-
コンタクト:
- Study Coordinator
- 電話番号:+358406682951
-
-
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、ポーランド、02-781
- 募集
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
-
コンタクト:
- Study Coordinator
- 電話番号:48 22 546 23 36
-
-
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210000
- 募集
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School ( Site 0318)
-
コンタクト:
- Study Coordinator
- 電話番号:+8602568182222
-
-
Jiangxi
-
Nanchang、Jiangxi、中国、330209
- 募集
- The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 0306)
-
コンタクト:
- Study Coordinator
- 電話番号:+86 791 8631 9333
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200032
- 募集
- Zhongshan Hospital Fudan University ( Site 0319)
-
コンタクト:
- Study Coordinator
- 電話番号:+8615000229853
-
-
Sichuan
-
Chengdu、Sichuan、中国、610066
- 募集
- West China Hospital, Sichuan University ( Site 0315)
-
コンタクト:
- Study Coordinator
- 電話番号:+8618980602252
-
-
-
-
-
Seoul、韓国、03722
- 募集
- Severance Hospital Yonsei University Health System ( Site 0080)
-
コンタクト:
- Study Coordinator
- 電話番号:+82222280880
-
-
-
-
-
Central、香港、0000
- 募集
- Hong Kong Integrated Oncology Centre ( Site 0232)
-
コンタクト:
- Study Coordinator
- 電話番号:+85237006888
-
Hong Kong、香港
- 募集
- Queen Mary Hospital ( Site 0230)
-
コンタクト:
- Study Coordinator
- 電話番号:+85222551727
-
Kowloon、香港
- 募集
- Hong Kong United Oncology Centre ( Site 0231)
-
コンタクト:
- Study Coordinator
- 電話番号:+852 2386 8002
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)
- Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations
- Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated
- Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and/or ≤Grade 2 neuropathy and/or endocrine-related AEs adequately treated with hormone replacement
- Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected
- Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive
- Has undetectable hepatitis C (HCV) viral load if HCV-infected
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
- Has HIV-infection with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
- Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
- Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to >470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention
- Has received prior systemic anticancer therapy for advanced or metastatic NSCLC
- Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis
- Has received previous treatment with an agent targeting KRAS
- Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation/randomization
- Has received radiation therapy to the lung that is >30 Gray within 6 months of start of study intervention
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed
- Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A- Pembrolizumab + MK-1084
Participants receive 400 mg of Pembrolizumab every 6 weeks and MK-1084 dose regimen. |
Oral Administration Intravenous administration
他の名前:
|
|
実験的:Arm B- Pembrolizumab + MK-1084 + Cetuximab
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and Cetuximab 500 mg/m^2 every 2 weeks. |
Intravenous administration Oral Administration Intravenous administration
他の名前:
|
|
実験的:Arm C- Pembrolizumab + MK-1084 + sacituzumab tirumotecan (sac-TMT)
Participants receive 400 mg of Pembrolizumab every 6 weeks, MK-1084 dose regimen, and 4 mg/kg sacituzumab tirumotecan (sac-TMT) every 2 weeks. |
Oral Administration Intravenous administration
他の名前:
Injection powder for intravenous infusion
他の名前:
Participants receive the following rescue medications, per approved product label, as premedication to study treatment to prevent hypersensitivity and/or infusion reactions: diphenhydramine (or equivalent histamine-1 [Hl] receptor antagonist), H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, and granulocyte colony-stimulating factor (G-CSF). A steroid mouthwash (dexamethasone or equivalent) will be given as prophylaxis for stomatitis/oral mucositis. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants with a Dose Limiting Toxicity (DLT)
時間枠:Up to approximately 21 days
|
A DLT is defined as the occurrence of protocol-specified toxicities if assessed by the investigator to be possibly, probably, or definitely related to study intervention administration, excluding toxicities clearly not related to the drug. |
Up to approximately 21 days
|
|
Percentage of Participants who Experience at Least One Adverse Event (AE)
時間枠:Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Percentage of Participants who Discontinue Study Intervention Due to an AE
時間枠:Up to approximately 84 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. |
Up to approximately 84 months
|
|
Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR)
時間枠:Up to approximately 84 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience CR or PR as assessed by BICR will be presented. |
Up to approximately 84 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of Response (DOR) per RECIST 1.1 as assessed by BICR
時間枠:Up to approximately 84 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR
時間枠:Up to approximately 84 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 84 months
|
|
Overall Survival (OS)
時間枠:Up to approximately 84 months
|
OS, defined as the time from first dose or randomization (depending on study period) to death due to any cause. OS will be presented. |
Up to approximately 84 months
|
|
Area Under the Concentration-Time Curve (AUC) for MK-1084
時間枠:At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to determine the AUC of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Maximum Concentration (Cmax) of MK-1084
時間枠:At designated timepoints (up to approximately 44 days)
|
Blood samples will be collected to estimate Cmax of MK-1084. |
At designated timepoints (up to approximately 44 days)
|
|
Trough Concentration (Ctrough) of MK-1084
時間枠:At designated timepoints (up to approximately 84 months)
|
Blood samples will be collected to determine the Ctrough of MK-1084. |
At designated timepoints (up to approximately 84 months)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Medical Director、Merck Sharp & Dohme LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 3475-01J
- U1111-1321-3999 (レジストリ識別子:UTN)
- 2025-521939-36-00 (レジストリ識別子:EU CT)
- 2025 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。